GSK plc (LON:GSK) Insider Buys £7,820.75 in Stock

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker purchased 545 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of GBX 1,435 ($19.69) per share, with a total value of £7,820.75 ($10,732.47).

GSK Stock Performance

Shares of LON:GSK traded up GBX 0.50 ($0.01) on Thursday, hitting GBX 1,395 ($19.14). The company's stock had a trading volume of 12,974,224 shares, compared to its average volume of 14,446,446. GSK plc has a 12 month low of GBX 1,242.50 ($17.05) and a 12 month high of GBX 1,678.68 ($23.04). The company has a market capitalization of £56.61 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The stock's 50-day moving average is GBX 1,432.03 and its two-hundred day moving average is GBX 1,414.17. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.62) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts forecast that GSK plc will post 175.980975 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research note on Friday, March 28th. Shore Capital reissued a "buy" rating on shares of GSK in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to data from MarketBeat, GSK presently has a consensus rating of "Moderate Buy" and an average target price of GBX 1,862.50 ($25.56).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.